Potential target for type 1 diabetes treatment
Researchers have discovered a new pathway to the regeneration of insulin in pancreatic stem cells, findings that could move towards new therapies for type 1 and type 2 diabetes.
List view / Grid view
Researchers have discovered a new pathway to the regeneration of insulin in pancreatic stem cells, findings that could move towards new therapies for type 1 and type 2 diabetes.
The new study highlights 11 genes which could be considered as potential candidates for novel therapeutics for type 1 diabetes.
Scientists have developed a novel type 1 diabetes treatment that involves transplanting pancreas cells that produce insulin.
In a new study, researchers from Osaka University have highlighted that mesenchymal stem cells could repress type 1 diabetes caused by cancer drugs.
A new study has identified harmful cellular pathways that prevent insulin production, presenting a drug target for diabetes.
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
A study has shown that inhibiting the REST gene boosted insulin-producing cells during early pancreas development in animals.
JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
Scientists have developed an implant that releases insulin-secreting cells which has shown success at treating diabetes in mice.
Combining two genomic methodologies, researchers have shown that pancreatic exocrine cells are implicated in type 1 diabetes.
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.